Is Turning Point Brands Stock a Buy After Investment Firm Cannell Capital Raises Its Stake to Nearly $20 Million?

Cannell Capital significantly increased its stake in Turning Point Brands (TPB) during Q3, adding 119,821 shares to reach 180,100 shares valued at $17.80 million, now representing 2.71% of its AUM. This substantial increase reflects TPB's robust financial performance, including a 75% share price surge over the past year, 31% year-over-year Q3 sales growth, and a 628% increase in Modern Oral product sales, leading to a significantly raised 2025 forecast for that segment. Cannell's heightened conviction underscores TPB's strong momentum in the consumer products sector, though the article notes a rising P/E ratio.

Analysis

Cannell Capital significantly increased its position in Turning Point Brands (TPB) during Q3 2025, adding 119,821 shares to reach a total of 180,100 shares, valued at $17.80 million. This move elevates TPB to 2.71% of Cannell's assets under management, up from 1.4% in Q2, signaling strong conviction. TPB's stock has surged 75% over the past year, outperforming the S&P 500 by 62 percentage points, reflecting robust market performance.

The company reported exceptional Q3 results, with sales growing 31% year-over-year to $119 million and net income increasing 70% to $21 million, yielding diluted EPS of $1.13. A primary driver of this growth was the Modern Oral nicotine pouch line, which saw Q3 sales soar 628% year-over-year to $37 million. This strong performance led management to significantly raise its 2025 Modern Oral sales forecast to $125-$130 million, from an initial $60-$80 million.

TPB's outstanding Q3 results propelled its shares to a 52-week high of $110.55 on November 5th. While the company demonstrates strong operational momentum and strategic success in diversified consumer products, its price-to-earnings (P/E) ratio has steadily increased throughout 2025. This suggests a potentially elevated valuation, which investors should consider.

Key Decisions for Investors

• Evaluate TPB's growth trajectory and market position, particularly the sustained strong performance in the Modern Oral segment, for long-term investment potential.
• Monitor valuation metrics, such as the P/E ratio, against growth prospects and industry peers given the significant stock appreciation and potentially elevated valuation.
• Observe future SEC filings from Cannell Capital for further insights into their conviction and any changes in their substantial TPB holding as a signal of institutional sentiment.